Antares Pharma (NASDAQ: ATRS) and DENTSPLY SIRONA (NASDAQ:XRAY) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
This is a breakdown of current ratings and price targets for Antares Pharma and DENTSPLY SIRONA, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
34.7% of Antares Pharma shares are owned by institutional investors. Comparatively, 96.5% of DENTSPLY SIRONA shares are owned by institutional investors. 11.6% of Antares Pharma shares are owned by insiders. Comparatively, 2.0% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Antares Pharma and DENTSPLY SIRONA’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Antares Pharma and DENTSPLY SIRONA’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Antares Pharma||$52.22 million||7.17||-$24.33 million||($0.11)||-21.73|
|DENTSPLY SIRONA||$3.75 billion||3.58||$429.90 million||($3.48)||-16.79|
DENTSPLY SIRONA has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.
DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. Antares Pharma does not pay a dividend. DENTSPLY SIRONA pays out -10.1% of its earnings in the form of a dividend.
Risk & Volatility
Antares Pharma has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
DENTSPLY SIRONA beats Antares Pharma on 11 of the 17 factors compared between the two stocks.
Antares Pharma Company Profile
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.